CClinicalTrials.gg
Sign In
CompletedNCT07157085Updated Sep 5, 2025

AI Multitask Model for HCC Treatment

An observational study in Hepatocellular Carcinoma (HCC), sponsored by Sun Yat-sen University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Sun Yat-sen University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
7,000
Ages
18 Years to 75 Years
Sex
All
01

Study summary

We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. The resulting tool will be prospectively deployed to guide personalized surgical, TACE, and systemic therapy decisions.

02

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • HCC
  • artificial intelligence
  • multitask deep learning
  • clinical decision support
03

In context

Carcinoma, Hepatocellular

3,182 studies on the registry are indexed under Carcinoma, Hepatocellular; 953 are open to participants now.

This study's enrollment of 7,000 is above the median of 200 across 752 observational studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with HCC received comprehensive therapies such as liver resection, ablation, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy

Inclusion criteria

  1. age 18-75 years;
  2. HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria)
  3. Eastern Cooperative Oncology Group performance status \< 2;
  4. Child-Pugh class A or B liver function;

Exclusion criteria

Exclusion Criteria:

  1. HCC combined with other malignancies;
  2. missing image data during perioperative period;
  3. lost to follow-up > 12 months.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
7,000 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherComprehensive treatment

    Comprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival

    from diagnosis of HCC to death or last follow-up

    Time frame: 60 months

Secondary outcomes

  1. Progression-free survival

    from diagnosis of HCC to disease progression or last follow-up

    Time frame: 60 months

07

Study locations

1 site
  • Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07157085
Lead sponsor
Sun Yat-sen University
Responsible party
Zhen-Wei Peng (Professor, Sun Yat-sen University) — Principal investigator
First posted
Sep 5, 2025
Start date
Jan 1, 2008
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
Sep 5, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma, Hepatocellular→

Other studies from this sponsor

Sun Yat-sen University

Start the discussion